| [1] | VANTYGHEM MC,PRESS M. Management strategies for brittle diabetes[J]. Ann Endocrinol(Paris),2006,67(4):287-296. |
| [2] | AMETOV AS,KULIDZHANIAN NK. Diabetes mellitus is an independent risk factor for cardiovascular disease[J]. Ter Arkh,2012,84:91-94. |
| [3] | KIM D,WANG L,BECONI M,et al. (2R)-4-oxo-4-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine:a potent,orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2005,48(6):141-151. |
| [4] | DRUKER DJ, NAUCK MA. GLP-1R agonists(incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes[J]. Lancet, 2006, 368(3):1696-1705. |
| [5] | DRUCKER DJ. Enhancing incretin action for the treatment of type 2 diabetes[J]. Diabetes Care,2003,26(10):2929-2940. |
| [6] | LIU XM. Special complication of diabetes[M]//LIU Xinmin. Practical endocrinology. 2nd ed. Beijing:People's Military Medical Publishing House, 1997:356-358. |
| [7] | 郭慧,刘良专,刘江华. 降脂通络软胶囊联合瑞舒伐他汀对2型糖尿病合并高血脂症患者效果观察[J]. 重庆医学,2015,44(24):3348-3349. |
| [8] | HOLST JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide 1[J]. Diabetes Metab Res Rev,2002,18(6):430-441. |
| [9] | 徐晓菲,吴玉波,吴禹蒙. 西格列汀对2型糖尿病患者血脂水平影响的系统评价[J]. 中国药房,2015,26(6):784-787. |
| [10] | 罗娜,朱妍,张真稳,等. 西格列汀联合胰岛素治疗脆性糖尿病的临床观察[J]. 中南大学学报(医学版),2015,40(10):1089-1095. |